The addition of radiation to the entire neuraxis and chemotherapy may increase the disease-free survival.

Radiation and/or chemotherapy had no significant effect in improving patients' disease-free survival.

It is not known whether factors peculiar to men with hemophilia may increase their chances of disease-free survival.

In multivariate analysis, karyotype was the most important predictor of disease-free survival.

Doxorubicin-based combination chemotherapy produces long-term disease-free survival in 35% to 45% of patients.

The expectations for node-negative cancer are usually 85 percent to 95 percent disease-free survival.

Unlike many other physical side effects of cancer treatment, sexual problems may not resolve within the first year or two of disease-free survival.

Continuous 5-year disease-free survival may be possible in as many as 33% of T1 patients.

In the disease-free survival, the event is relapse rather than death.

Very few people say cure rate; we talk about long-term disease-free survival.